A single dose, and effects still visible a month out

Researchers at UC San Francisco and Imperial College London have published findings showing that one dose of psilocybin, the psychoactive compound found in psilocybin mushrooms, produced measurable changes in brain function and likely brain structure that remained detectable a full month after the experience. The study, published in Nature Communications, was conducted in 28 healthy adults who had never previously used a psychedelic substance — a deliberate design choice meant to isolate the drug's direct neurological effects from any confounding influence tied to prior psychedelic experience or an existing mental health diagnosis.

Senior author Robin Carhart-Harris, the Ralph Metzner Distinguished Professor of Neurology at UCSF, framed the significance of the findings in terms of mechanism rather than simply outcome: "We already knew psilocybin could be helpful for treating mental illness. But now we have a much better understanding of how." That distinction matters, because psilocybin's therapeutic promise for conditions including depression, anxiety, and addiction has been documented across a growing body of clinical research in recent years — what's remained less clear is the specific biological process connecting a single guided psychedelic experience to improvements in mental health that researchers have observed persisting for weeks or months afterward.

How the experiment was structured to isolate the drug's real effect

The study followed a careful two-phase design specifically intended to give researchers a genuine before-and-after comparison. In the first session, all 28 participants received a 1-milligram dose of psilocybin — a dose low enough that researchers treated it functionally as a placebo, since it's not sufficient to produce a meaningful psychedelic experience. Researchers then tracked participants' brain activity and structure over the following weeks using several distinct imaging and measurement techniques: electroencephalography, or EEG, which records electrical brain activity through electrodes placed on the scalp; functional MRI, which measures brain activity by tracking blood flow; and diffusion tensor imaging, or DTI, a specialized MRI technique that measures the movement of water molecules along the brain's neural pathways to assess the structural integrity of connections between brain regions.

A month later, those same participants returned for a second session and received a considerably higher, 25-milligram dose of psilocybin — enough to reliably produce a strong psychedelic experience. Researchers then repeated the identical battery of brain scans and psychological assessments, giving them a genuine within-subject comparison: the same individuals' brains and reported well-being, measured before and after a real psychedelic dose, rather than comparing entirely different groups of people to each other.

What happened in the brain during the peak experience itself

Within 60 minutes of receiving the 25-milligram dose, EEG recordings revealed a measurable increase in what researchers call brain entropy — a term describing the diversity and complexity of neural activity occurring in the brain. Dr. Taylor Lyons, the study's first author and a research associate at Imperial College London, explained the underlying concept: a high-entropy brain state means neural activity is processing a richer, less predictable range of information, moving away from the more rigid, repetitive patterns that typically characterize everyday brain function. "Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought," Lyons said.

That entropy increase wasn't simply a passing measurement disconnected from how participants actually felt or subsequently behaved. The degree of entropy each individual experienced during the psychedelic session predicted how much psychological insight — a form of emotional self-awareness and perspective-shifting — participants reported the following day. That link between a specific, objectively measured brain state and a subjectively reported psychological outcome is what gives this research its explanatory power, connecting a physiological process directly to something participants could actually describe and researchers could reliably track.

The month-later scans that surprised researchers most

The most striking findings in this study came from what researchers observed a full month after the high-dose session, well beyond the acute psychedelic experience itself. Diffusion tensor imaging revealed that participants' neural tracts — the bundles of nerve fibers connecting different brain regions and allowing signals to travel between them — were denser and showed greater structural integrity than they had before the 25-milligram dose. Researchers describe this as functionally the opposite of what typically happens to these same neural pathways during normal aging, a process that generally makes these connections more diffuse and less structurally intact over time.

The most pronounced changes appeared specifically in pathways connecting the front and middle regions of the brain — areas associated with self-reflection, emotional regulation, and decision-making. That specific location is notable given what these regions are understood to govern: functions directly relevant to exactly the kind of psychological insight and perspective shift researchers were tracking as an outcome of the psychedelic experience itself.

Connecting the dots: entropy, insight, and lasting well-being

The chain of evidence this study lays out moves through three connected steps. First, participants who experienced the greatest increase in brain entropy during the psychedelic session were the ones most likely to report meaningful psychological insight the following day. Second, that reported insight predicted improvements in overall well-being measured a month later. Third, the structural brain changes observed via DTI at that one-month mark correlated with decreased brain network modularity on functional MRI over that same period — meaning the brain's different functional regions appeared to be operating in a less rigidly compartmentalized way even a month after the actual drug had left participants' systems entirely.

Carhart-Harris connected this full sequence directly to how psychedelic-assisted therapy likely produces its documented clinical benefits: "It suggests that the trip — and its correlates in the brain — is a key component of how psychedelic therapy works." That's a meaningful claim within the broader psychedelic research field, where some researchers have explored whether it might eventually be possible to develop psilocybin-derived compounds that produce therapeutic benefit without the accompanying subjective psychedelic experience. This study's findings push in the opposite direction, suggesting the trip itself — and the elevated brain entropy state it produces — may be mechanistically central to the treatment's lasting effects, rather than an incidental side effect that could someday be engineered away.

What this research can't yet tell us

It's important to be precise about this study's real limitations. The sample size was modest, just 28 participants, and all were healthy adults with no diagnosed mental health conditions — meaning these findings describe how psilocybin affects a psychologically healthy brain, not necessarily how the same mechanisms operate in people living with depression, anxiety, or addiction, the populations where psilocybin-assisted therapy has generated the most clinical interest. Researchers themselves have noted a further practical limitation: because a 25-milligram dose produces such a pronounced subjective experience, it was generally obvious to participants which session involved the active drug and which involved the low-dose placebo — a detail that somewhat limits how cleanly the study can rule out expectation or psychological anticipation as a contributing factor to the reported outcomes.

Those caveats don't undermine the value of what this research demonstrates, but they do mean its findings should be understood as a mechanistic exploration in a controlled research setting, not a conclusion about how psilocybin should be used therapeutically or a substitute for guidance from a licensed medical professional in any clinical context.

Why understanding the mechanism actually matters for future treatment

Beyond its scientific interest, this research carries a specific practical implication for how psychedelic-assisted therapy might eventually be refined. If brain entropy during the psychedelic experience genuinely predicts the degree of psychological insight and subsequent well-being improvement a patient experiences, that gives researchers and clinicians a measurable target to work toward — potentially informing how dosing is calibrated to reliably produce the kind of brain state associated with the strongest and most durable therapeutic benefit, rather than treating dose selection as a less precise, largely empirical process.

That's a meaningfully different, more mechanistically grounded approach to psychedelic treatment design than simply replicating dosing protocols that have shown general clinical benefit in prior trials without fully understanding why those particular doses worked. Whether this specific brain-entropy framework holds up as consistently in clinical populations with diagnosed mental health conditions, and whether it can genuinely be used to individualize and optimize psychedelic-assisted treatment protocols going forward, remains a question for the larger, more clinically focused trials this foundational research is likely to help inform.

*This article was researched using publicly available reporting from Nature Communications, UC San Francisco, ScienceDaily, Medical Xpress, Technology Networks, News-Medical, The Debrief, and ScienceAlert's coverage of the peer-reviewed study led by Dr. Taylor Lyons and Professor Robin Carhart-Harris. It is intended for informational purposes and is not medical advice. Psilocybin remains a controlled substance in most jurisdictions outside of approved clinical research or specific legal frameworks; anyone considering psychedelic-assisted therapy should consult a licensed medical or mental health professional.*